Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR105 in Advanced Malignant Tumors
NCT05351697Phase 1Terminated
- Sponsor
- BioRay Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of br105 in malignant neoplasms (advanced stage), non-Hodgkin lymphoma (NHL) and gastric cancer (GC), sponsored by BioRay Pharmaceutical. Primary endpoints: Dose Limiting Toxicity up to 3 weeks, Maximum Tolerated Dose up to 3 weeks and 3 more. Started Apr 2022; status: terminated.
02
Drugs
br105
03
Conditions
malignant neoplasms (advanced stage)non-Hodgkin lymphoma (NHL)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05351697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351697.